Compare TG Therapeutics Inc (TGTX) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Tapestry, Inc. — how do they compare? TG Therapeutics Inc trades at $54.83 (market cap $8.16B), while Tapestry, Inc. trades at $116.02 (market cap $23.09B). The key difference: Tapestry, Inc. is far larger — about 2.8× TG Therapeutics Inc's market cap, and Tapestry, Inc. pays a 1.6% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Tapestry, Inc. for 70 Days on average.
| TGTX | TPR | |
|---|---|---|
Market Cap | $8.16B | $23.09B |
Volume | 1,735,121 | 2,745,259 |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $164.78 |
52-Week Low | $26.94 | $98.81 |
Typical Hold Time | 16 Days | 70 Days |
Enterprise Value | $8.37B | $25.89B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
TPR trades at $116.26, up 2.53% today, with a bearish technical signal but strong analyst consensus. Recent earnings beats and a high ROE of 197.14% highlight operational strength, though net income margin fell sharply in 2025. The stock is supported by a $174.64 consensus price target and positive news on international growth, but faces risks from tariffs and Kate Spade execution challenges.
Outlook remains positive with 73% buy ratings and projected revenue growth to $8.0B in 2026. Key opportunities include margin expansion and Coach brand momentum, while risks involve volatile cash flows, high debt, and competitive pressures. The current price offers a 50% upside to the consensus target, but investors should monitor earnings delivery and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
